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Chemical–genetic attenuation of focal neocortical
seizures
Dennis Ka¨tzel1, Elizabeth Nicholson1, Stephanie Schorge1, Matthew C. Walker1 & Dimitri M. Kullmann1
Focal epilepsy is commonly pharmacoresistant, and resective surgery is often contraindicated
by proximity to eloquent cortex. Many patients have no effective treatment options. Gene
therapy allows cell-type speciﬁc inhibition of neuronal excitability, but on-demand seizure
suppression has only been achieved with optogenetics, which requires invasive light delivery.
Here we test a combined chemical–genetic approach to achieve localized suppression of
neuronal excitability in a seizure focus, using viral expression of the modiﬁed muscarinic
receptor hM4Di. hM4Di has no effect in the absence of its selective, normally inactive and
orally bioavailable agonist clozapine-N-oxide (CNO). Systemic administration of CNO
suppresses focal seizures evoked by two different chemoconvulsants, pilocarpine and
picrotoxin. CNO also has a robust anti-seizure effect in a chronic model of focal neocortical
epilepsy. Chemical–genetic seizure attenuation holds promise as a novel approach to
treat intractable focal epilepsy while minimizing disruption of normal circuit function in
untransduced brain regions or in the absence of the speciﬁc ligand.
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E
pilepsy affects up to 1% of the population1 and is resistant
to drug therapy in at least 20% of cases2. Epilepsy can be
focal (arising from a speciﬁc brain area) or generalized
(arising from both hemispheres). People with focal-onset epilepsy
are especially prone to pharmacoresistance3. The epileptogenic
zone in such cases is frequently restricted to a small region that
can often be localized with imaging and electrophysiological
techniques4. However, surgical removal of the seizure focus can
successfully treat only about 5% of pharmacoresistant patients,
and is often inappropriate in focal neocortical epilepsy because of
proximity to eloquent cortex5,6.
Gene therapy targeted to the epileptogenic zone has been
shown to be effective in rodent models of epilepsy including focal
neocortical epilepsy7. However, viral delivery of transgenes that
alter excitability permanently may impair essential function of
circuits near the seizure focus. An attractive strategy would be to
suppress circuit excitability ‘on demand’ upon detection of a
seizure. Recently, progress in optogenetic seizure suppression in
rodents has shown that this is, in principle, feasible7–9. One of the
main limitations to clinical translation is the need to deliver light
of the appropriate wavelength, intensity and duration to the
region of transduced neurons. This necessitates the implantation
of optical devices and suffers from the strong attenuation of light
in brain tissue.
We report an alternative gene therapy approach to achieve
targeted and temporally limited suppression of neuronal
excitability that relies on systemic delivery of a small molecule
inhibitor. Speciﬁcity is achieved by regional and cell-type speciﬁc
expression of a designer receptor exclusively activated by a
designer drug (DREADD). Neurons transduced with a DREADD
are in principle unaffected in the absence of the selective ligand,
and only affected when the ligand is present, thereby avoiding
permanent alteration of their properties10. We chose the
engineered inhibitory Gi-coupled human muscarinic receptor
hM4Di, which has been made sensitive to the orally bioavailable
and normally inert metabolite of clozapine, clozapine-N-oxide
(CNO)11,12. Importantly, hM4Di is relatively insensitive to
acetylcholine, the endogenous agonist of the parent receptor.
hM4Di activation leads to the opening of G-protein gated
inwardly rectifying potassium channels, resulting in membrane
hyperpolarization and neuronal inhibition11.
Results
Chemical–genetic silencing of pilocarpine-induced seizures.
To test the ability of the DREADD to modify seizure activity,
we injected an adeno-associated virus (AAV) encoding hM4Di
under the CamkIIa promoter (AAV5-CaMKIIa-HA-hM4D(Gi)-
IRES-mCitrine) into the forelimb area of primary motor cortex
(M1) of rats weighing 263–325 g under isoﬂurane anaesthesia. At
the same time we implanted both a Teﬂon cannula guide above
the injection site to allow administration of chemoconvulsants
and a subcutaneous transmitter (Open Source Instruments Inc.)
with the active lead overlying M1 for wireless electro-
encephalography (EEG) recording. The transmitter
samples the EEG at 512Hz continuously for several weeks13.
Expression of hM4Di (Fig. 1a,b) had no detectable effect on
behaviour or limb use (Fig. 1c), and was conﬁrmed by
ﬂuorescence microscopy for all rats sacriﬁced after 4–20 weeks.
We ﬁrst examined seizures acutely evoked by chemoconvulsant
injection into layer 5 of the motor cortex 17–52 days after hM4Di
AAV injection. Pilocarpine (5M, 200–900 nl) injected via the
implanted cannula guide (1.6–2.0mm from skull surface) elicited
large-amplitude spike-wave deﬂections at a frequency between 0.5
and 2Hz, starting within 5min of injection and lasting between
45 and 90min (Fig. 2a,b). Spike-wave complexes either had a
single negative peak (‘simple’ spike-waves, SS) or featured one or
more shoulders (polyspike-waves or ‘complex’ spike-waves, CS;
Fig. 2b). They were interspersed with runs of intermediate
frequency (IF) discharges (5–12Hz) lasting 0.2–12 s, which
typically had a smaller amplitude (Fig. 2b). IF discharges
correlated with the occurrence of more severe motor seizures.
Motor seizures ranged from brief twitches of the contralateral
limb, the head or the body (score 1), repetitive head, limb or body
shaking (score 2), to rearing, retrograde locomotion and
generalized convulsions lasting several seconds (score 3)
(Fig. 2c). We therefore used the EEG power in an overlapping
frequency band (4–14Hz) as a surrogate marker to assess the
anti-seizure effect of hM4Di activation.
We randomly interleaved experiments on alternate days
on which either CNO (1mg kg 1 in dimethyl sulfoxide
(DMSO)/saline vehicle)12, or vehicle alone, was administered by
intraperitoneal injection immediately after focal neocortical
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Figure 1 | Expression and tolerability of HA-hM4Di-mCitrine.
(a) Expression of HA-hM4Di-mCitrine in deeper layers of right primary
motor cortex (M1), visualized with anti-HA antibody. Scale, 100mm.
(b) Colocalization of CamKIIa-HA-hM4Di-mCitrine, visualized with anti-HA
(green) and anti-CamKIIa (red) antibodies. Scale, 20mm. (c) Motor
coordination with (right) and without (left) intraperitoneal CNO in rats
receiving sham injection (red) or HA-hM4Di-mCitrine in right M1 (blue).
Foot faults for the left forelimb (contralateral to HA-hM4Di-mCitrine) were
compared with the right (ipsilateral) forelimb (paired t-test) and with foot
faults of the left forelimb of sham-injected animals (unpaired t-test;
mean±s.e.m., n¼ 5 sham-operated and 7 hM4-injected rats). NS: P40.05.
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pilocarpine infusion. In CNO trials, both electrographic and
motor convulsions were substantially reduced (n¼ 6 rats).
Repeated measures analysis of variance (ANOVA) for the ﬁrst
six 10min intervals post vehicle/CNO injection revealed a
signiﬁcant decrease in the mean frequency of negative
deﬂections in the EEG, the mean 4–14Hz power, and the
number of IF runs that correlate with severe motor seizures
(Fig. 2c,d; Po0.05). The seizure activity was on average larger in
the vehicle trial than in the matched CNO trial for each rat and
every 10min interval (Fig. 2e,f).
Chemical–genetic silencing of picrotoxin-induced acute
seizures. CNO thus profoundly suppressed pilocarpine-triggered
seizures. However, the interpretation of this anti-seizure effect is
potentially confounded by an overlap of downstream signalling
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Figure 2 | Chemical–genetic silencing of pilocarpine-induced seizures. (a) Morlet-wavelet EEG spectra from a rat administered intracortical pilocarpine
(time 0), with either intraperitoneal vehicle (top) or CNO (bottom). (b) EEG segment from (a, top), showing simple spikes (SS), complex spikes (CS) and
runs of intermediate frequency (IF) activity (expanded below). (c) Behavioural seizures correlated with EEG. SS activity was associated with no motor
seizures (severity score 0) or twitching of limb, head or body (score 1), while IF was associated with repetitive head or body shaking (score 2) or rearing,
retrograde locomotion and generalized convulsions (3). Six hundred consecutive 4-s-intervals per rat were assessed in three rats (numbered 1–3).
(d) Detection of Intermediate Frequency (IF)-activity by Fourier transformation: Fourier transform (right) of EEG segments in one rat showing either
SS (black) or IF (red) activity (two 5-s periods shown to the left) induced by pilocarpine. The IF Fourier transform shows a peak around 7Hz (and a
harmonic at 14Hz). (e) Temporal evolution of spike frequency (left), 4–14Hz power (middle), and number of IF runs (right), in vehicle (red) and CNO
(blue) trials (consecutive 10-min-intervals before (-10–0min) and after pilocarpine and vehicle/CNO injection). N¼ 6 rats (10 pairs of trials, averaged
within rat where repeated, data are shown as mean±s.e.m.). (f) Same data as in e, but plotted as cumulative electrographic seizure metrics (frequency,
power, number of IF events), comparing vehicle versus CNO for each animal (indicated by colour). Symbols indicate consecutive cumulative metrics at
10-min-intervals. The 45-degree line (grey) indicates equivalence of CNO and vehicle.
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cascades of pilocarpine acting on muscarinic receptors and
CNO acting on hM4Di14. We therefore tested a second
chemoconvulsant, the GABAA receptor blocker, picrotoxin.
Picrotoxin injection into the primary motor cortex (10mM,
100–600 nl) also elicited electrographic and motor seizures. These
were similar in overall duration, composition of spike-wave and
IF complexes, and behavioural correlates (Fig. 3a–d) to seizures
caused by pilocarpine. Among minor differences, electrographic
bursting switched on and off more abruptly and individual
polyspike-wave complexes lasted longer (Fig. 3b). When CNO
was administered by intraperitoneal injection immediately after
focal picrotoxin the electrographic discharges were again
attenuated (Fig. 3e; n¼ 5 rats; repeated measures ANOVA,
Po0.05). This was especially marked for IF activity (Fig. 3e,f),
which correlated with more severe motor seizures (Fig. 3c,d).
We asked whether off-target effects of CNO independent of
hM4Di could account for its anti-seizure effect. We conducted
control experiments in both, rats injected with an analogous virus
expressing the optogenetic actuator ArchT instead of hM4Di as
well as rats, which had no virus injected. Animals underwent the
same experimental protocol as described above, using local
intracortical injection of either pilocarpine (six virus-injected and
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Figure 3 | Chemical–genetic silencing of picrotoxin-induced seizures. (a) Morlet-wavelet power spectra of EEG in an animal injected with picrotoxin
at time 0 (1mm below pia, 10mM, 300nl), together with intraperitoneal vehicle (top) or 1mgml 1 CNO in vehicle (bottom) on consecutive days. (b) EEG
activity. Bottom, expanded sections from times indicated (2-s-duration) showing SS, CS and IF activity. (c) Motor seizures were more severe in association
with IF activity than with SS activity, and intermediate with CS activity (severity scale as in Fig. 2c). Six hundred consecutive 4-s-intervals per rat were
assessed in three rats (numbered 1–3). (d) Fourier transform (right) of 5-s-traces displayed (left, middle) containing SS (black) and IF (4–14Hz, peak
around 11.5Hz; red) activity induced by picrotoxin. (e) Temporal evolution of spike frequency (left), 4–14Hz power (middle), and number of IF runs (right),
in vehicle (red) and CNO (blue) trials (consecutive 10-min-intervals before ( 10–0min) and after picrotoxin and vehicle/CNO injection). N¼ 5 rats (12
pairs of trials, averaged within rat where repeated, mean±s.e.m.). (f) Same data as in e, but plotted as cumulative electrographic seizure metrics for each
animal as in Fig. 2e.
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ﬁve uninjected rats; Fig. 4a,b) or picrotoxin (ﬁve virus-injected
and six uninjected rats; Fig. 4c,d). We observed no signiﬁcant
reduction of seizure activity in CNO compared with vehicle trials
in any of the three measures of seizure severity in any of the
control groups (repeated measures ANOVA, P40.05).
Finally, we asked if chemical–genetic inhibition of focal seizure
activity would result in a signiﬁcant reduction of behavioural
seizures. We focused on the picrotoxin model, where the anti-
seizure effect of CNO/hM4Di was less pronounced, to establish
a conservative benchmark. Rats (n¼ 7) underwent a similar
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Figure 4 | Effect of CNO on chemically induced seizures in control rats. Two distinct control groups per condition were tested: rats injected with an
AAV5-CamKIIa-ArchT-GFP virus, and rats which were not injected with a virus (but otherwise underwent the same surgery and implantations as the other
groups). For panels (a) and (c) data from both groups were pooled, while in panels (b) and (d) data from all rats and groups are shown individually.
(a) Temporal evolution of spike frequency (left), 4–14Hz power (middle), and number of IF runs (right), in vehicle (grey) and CNO (black) trials
(consecutive 10-minute intervals before (—10–0min) and after pilocarpine and vehicle/CNO injection. N¼ 6 ArchT-virus transfected and ﬁve
untransfected rats (two pairs of trials per animal, which were averaged within each rat; mean±s.e.m.). (b) Same data as in a, but plotted as cumulative
seizure metrics for each individual animal (indicated by colour; blue hues with triangle symbols indicate untransfected animals, red hues with circles
indicate ArchT-transfected animals; display as in Fig. 2f). (c) Temporal evolution of spike frequency (left), 4–14Hz power (middle), and number of IF runs
(right), in vehicle (grey) and CNO (black) trials (consecutive 10-min-intervals before and after picrotoxin and vehicle/CNO injection. N¼ 5 ArchT-
transfected and six untransfected rats (two pairs of trials averaged within each rat; one animal in the ArchT-group contributed only one pair of trials;
mean±s.e.m.). (d) Same data as in c, but plotted as cumulative electrographic seizure metrics colour-coded as in b.
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treatment as before, but the virus was left to express for 3 months
before the ﬁrst experiment was conducted to achieve
high expression levels. Seizures of the most severe class (score
3, see above and Methods) were counted by an experimenter who
was blind to the identity of the injected compound (vehicle versus
CNO, 4mg kg 1). The number of severe behavioural seizures
was reduced in CNO trials relative to vehicle trials in all subjects
(P¼ 0.012, paired t-test), with an average decrease of 39.5±8.7%
(mean±s.e.m., Fig. 5a) or 19.3 seizure episodes (Fig. 5c). No
effect was observed in control animals, which were not injected
with virus (n¼ 6; P¼ 0.510, paired t-Test, Fig. 5b).
Chemical–genetic silencing of focal neocortical epilepsy.
hM4Di activation with CNO is thus effective in two chemo-
convulsant models. Does it also suppress spontaneous seizures in
established epilepsy? We turned to the tetanus toxin model of
chronic epilepsy15,16, which responds poorly to antiepileptic
drugs and resembles human epilepsia partialis continua17.
This model is characterized by several EEG features, including
increased high-frequency (120–160Hz) power, increased
coastline (cumulative difference between successive points on
the EEG) and the occurrence of brief bursts of high-frequency
EEG activity that can be detected by an automated event
classiﬁer7 (Fig. 6a).
Although the half-life of CNO in rats has not been measured
systematically, it affects neurons transduced with hM4Di or its
excitatory analogue hM3Dq for at least 90min12,18,19, and is fully
cleared within 12 h of administration of its precursor clozapine20.
We therefore assessed electrographic markers of epilepsy during a
3.5-h window starting with the ﬁrst of two intraperitoneal
injections of either CNO or vehicle, with the second injection at
2 h. The assessment was then repeated 24 h later, switching
vehicle and CNO, to allow for washout of the agonist, and to
control for diurnal variability in seizure frequency (Fig. 6b–d, six
rats). All three measures of epilepsy (frequency of epileptiform
bursts, coastline and high-frequency power) were signiﬁcantly
attenuated by CNO when compared with vehicle (P¼ 0.028,
Wilcoxon test; n¼ 6).
hM4Di inhibits synaptic transmission. While the optogenetic
approach of on-demand silencing of epilepsy relies on direct
hyperpolarization via outward currents, the more indirect,
chemogenetic inhibition via hM4Di may recruit at least two
strategies of neuronal inhibition: ﬁrst, activation leads to the
opening of G-protein gated inwardly rectifying potassium
channels, resulting in membrane hyperpolarization11. Second,
synaptic transmission from excitatory cortical synapses might be
directly inhibited, as has been shown for the native muscarinic
receptor M4, which is expressed presynaptically21,22. While the
former hyperpolarizing effect has been repeatedly documented
for the modiﬁed receptor hM4Di, it is unclear if its potential for
synaptic silencing may also contribute to the inhibitory effect we
observe. We injected the hM4Di-expressing AAV into the CA3
subﬁeld of the hippocampus in three rats under isoﬂurane
anaesthesia at 4 weeks of age, and prepared acute hippocampal
slices 10–11 weeks later. A ﬁeld excitatory postsynaptic potential
(fEPSP) was evoked in stratum radiatum of CA1 by extracellular
stimulation. Bath perfusion of CNO (10 mM) reversibly decreased
the initial slope of the fEPSP without affecting the ﬁbre volley,
consistent with a decrease in glutamate release (n¼ 9 slices;
Fig. 7). Although the depression was modest, this experiment
underestimates the effect of hM4Di activation on individual
synapses because not all stimulated axons were supplied by
transduced neurons. The inhibition of synaptic transmission
likely contributes to the overall antiepileptic effect of hM4Di.
Discussion
This study shows that chemical–genetics offers the prospect
of attenuating seizures on demand. We demonstrate the
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(see ref. 7). (b–d) Pair-wise comparison of the frequency of epileptiform
events (b), coastline (c) and high-frequency power (d) between vehicle and
CNO trials. N¼ 6 rats; 15 pairs of trials, averaged within animal where
repeated. Orange bars indicate the decrease (%, right axis), where
signiﬁcant (Wilcoxon test; Po0.05).
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effectiveness of this treatment in two focal seizure models and one
model of focal neocortical epilepsy. Silencing was particularly
pronounced when seizures were elicited by focal pilocarpine
injection, but slightly less effective when picrotoxin was injected.
This difference might reﬂect the loss of endogenous GABAA
receptor-mediated inhibition in the latter model, making it
more difﬁcult for the network to stabilize when excitability is
reduced. Transduction with hM4Di has no effect on neuronal
excitability in the absence of its speciﬁc ligand CNO10–12, and so
this approach avoids the theoretical risk of gene therapies
designed around permanent overexpression of ion channels,
neurotransmitter receptors or neuropeptides. Its temporal
speciﬁcity does not match that of optogenetics7–9 because the
duration of effect is dictated by the half-life of CNO, which has
been estimated in humans at 7–8 h23. However, chemical–
genetics avoids the need for invasive and biocompatible devices
to deliver light to the transduced brain area close to the seizure
focus. Moreover, a relatively large area may be targeted, which is
not limited by absorption of light. Instead, CNO can be
administered systemically.
We observed a signiﬁcant reduction in seizure severity within
10min of CNO administration (Figs 2e,f and 3e,f), well below
the 30-min timepoint that usually deﬁnes status epilepticus. Many
patients with drug-resistant epilepsy have seizures that are
preceded by premonitory auras, or cluster at predictable times
(for example, catamenial epilepsy), and hence might beneﬁt from
such chemical–genetic silencing. CNO’s bioavailability implies
that it could be administered buccally or intranasally. For even
faster on-demand administration, subcutaneous pumps, as used
to deliver insulin24, could, in principle be used in people with
epilepsy. Recent evidence that seizures can be predicted by
automated EEG analysis25 offers the prospect of a closed-loop
device.
A further potential application of chemical–genetics to epilepsy
is to test the hypothesis that continued alteration of neuronal
excitability for a ﬁxed period might ‘reset’ epileptogenic circuits in
some circumstances, bringing about a persistent reduction in
seizures that outlasts the administration of the ligand. The
reversibility, together with the regional and cell-type speciﬁcity of
chemical–genetics, distinguishes this approach from available
small molecules or gene therapies based on expression of ion
channels or other signalling molecules.
In conclusion, we have shown that chemical–genetics is a
promising approach to achieve region- and cell-type speciﬁc
attenuation of neuronal excitability to suppress seizures. The
pathway to translation is likely to be more direct than for
optogenetics.
Methods
AAV of serotype 5 containing a CamkIIa-HA-hM4D(Gi)-IRES-mCitrine cassette
provided by Dr Bryan Roth (University of North Carolina, UNC) was obtained
from UNC Vector Core at a concentration of 8 1012 infectious units (IU) per ml.
For control experiments (Fig. 4) a similar virus was injected expressing the
optogenetic silencer ArchT instead of the chemical–genetic silencer hM4Di
(AAV5-CamkIIa-ArchT-GFP).
Stereotactic surgery. Animal experiments were conducted in accordance with the
Animals (Scientiﬁc Procedures) Act 1986, and approved by the local ethics com-
mittee. Male Sprague–Dawley rats (6–12 weeks old, 263–325 g) were anaesthetized
using isoﬂurane and placed in a sterotaxic frame (Kopf, CA, USA). hM4Di-
expressing AAV5-virus (1.5 ml) was injected at 100 nlmin 1 into layer 5 of the
forelimb area of right primary motor cortex (coordinates, 2.2–2.4mm lateral and
1.0mm anterior of bregma at a depth of 1.0mm from pia; in some rats half of the
volume each was deposited at 1.1 and at 0.7mm from pia). An EEG transmitter
(A3019D, Open Source Instruments13) was implanted subcutaneously with a
subdural intracranial recording electrode positioned above the injection site.
A reference electrode was implanted in the contralateral skull. For sequential
injections of chemoconvulsants a Teﬂon cannula guide (C313GT/SP, PlasticsOne)
was implanted above the injection site. For chronic epilepsy experiments, 12–16 ng
of tetanus toxin (gift of Dr G. Schiavo) was injected together with hM4Di-
expressing AAV5 virus in a ﬁnal volume of 1.6–1.8 ml. Animals were housed
separately in Faraday cages and EEG was recorded continuously for up to 8 weeks
post surgery. Animal numbers per cohort were chosen to allow for detection of a
therapeutic effect, while avoiding unnecessary procedures given their severity level.
Assessment of motor coordination. Rats were either injected with AAV5-
CamkIIa-HA-hM4D(Gi)-IRES-mCitrine unilaterally into the right-motor cortex
(as described above) or underwent sham surgery (cut and suturing of skin). After
25–32 days, rats were placed on an elevated metal grid for 3min. Two observers,
blind to whether the rat had undergone sham surgery or hM4Di-injection, counted
left and right forelimb foot faults. These were deﬁned as the whole foot falling
through the space between painted metal wires that made up the grid, spaced 4 cm
apart. Four hours later, all rats were injected with CNO (1mg kg 1) and the
behavioural assessment repeated 25–33min post-injection. Typically, the number
of foot faults was lower on the second assessment as a result of training and
habituation7. Two months later, the same rats were assessed in a similar manner,
but with the reverse order of treatment: the ﬁrst trial was conducted 24–37min
after injection of CNO, while the second trial was conducted B5.5 h later without
prior injection. Data from the two CNO and the two non-injection trials were each
averaged for analysis.
Brain slice experiments. AAV5-CamkIIa-HA-hM4D(Gi)-IRES-mCitrine virus
(1 ml) was injected into the CA3 subﬁeld of the dorsal hippocampus of 4-week-old
male Sprague–Dawley rats at 3.6mm lateral (right), 2.8mm posterior and 2.9mm
ventral from bregma at 100 nlmin 1 (ref. 26). Ten to eleven weeks later, the
animals were transcardially perfused with a room temperature solution containing
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Figure 7 | Chemical–genetic inhibition of synaptic transmission.
(a) Experimental conﬁguration; a stimulation electrode was placed in
stratum radiatum to activate Schaffer collateral ﬁbres expressing
HA-hM4Di-mCitrine. The resulting fEPSP, evoked every 30 s, was recorded
further medial in CA1 with an extracellular electrode. (b) Sample traces
showing a stimulation artifact, ﬁbre volley and subsequent fEPSP under
baseline condition (black), during CNO wash-in (10 mM; red) and after
washout (blue). (c) Average normalized slope of evoked fEPSPs (black) and
average normalized amplitude of evoked ﬁbre volleys over time before
(6min), during (10min) and after (6min) CNO (10 mM) across slices
(n¼9). Slices were only included if mCitrine ﬂuorescence was visible in
CA3 and CA1. Error bars show s.e.m.
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(in mM): N-Methyl-D-glucamine-Cl, 92; KCl, 2.5; NaH2PO4, 1.25; Thiourea, 2;
Ascorbic acid, 5; Na-Pyruvate, 3; MgCl2, 10; D-Glucose, 25; NaHCO3, 30; CaCl2,
0.5; Sucrose, 1 and horizontal hippocampal slices were prepared. The extracellular
perfusion solution contained (in mM): NaCl, 119; KCl, 2.5; CaCl2, 2.5; MgSO4, 1.3;
NaH2PO4, 1.25; NaHCO3, 25; and Glucose, 10. A fEPSP was evoked every 30 s by
extracellular stimulation (20–320 mA, 100 ms) in stratum radiatum of CA1, before,
during and after bath perfusion of CNO (10 mM).
Seizure models. Pilocarpine (5M in sterile saline) or picrotoxin (10mM in 10%
DMSO/sterile saline) were injected through the previously implanted Teﬂon
cannula guide 17–52 days after hM4Di AAV injection. The volume injected was
adjusted between 200 and 900 nl for pilocarpine and 100–600 nl for picrotoxin,
guided by the severity of the resulting seizures in each animal, and were kept
constant between matched CNO and vehicle trials. CNO (1mg kg 1, diluted at
1mgml 1 or 0.5mgml 1 in 1% DMSO/saline vehicle) or vehicle alone were
injected intraperitoneally immediately after convulsant infusion. Spike-waves
developed within 5min of chemoconvulsant injection. For assessment of the
inhibitory effect of hM4Di activation on picrotoxin-induced behavioural (motor)
seizures, experiments were conducted no earlier than 3 months after viral
transfection and at a dose of 4mg kg 1 CNO (in 4% DMSO/saline vehicle).
The experimenter, who graded (see below) and counted the seizures over 60min
starting 5min after CNO/vehicle injection, was blind to the identity of the injected
compound.
Epilepsy model. Tetanus toxin (12–16 ng) injected in a suspension with the
hM4Di-expressing virus (see above), evoked high-frequency (70–160Hz) events
typically lasting less than 1 s, starting within 4 days. Such events occurred for
up to 8 weeks after injection, but their frequency varied from day to day, and also
depending on the time of day. Therefore, pairs of CNO/vehicle trials were matched
according to time of day, and we set a criterion that at least two events per hour
had to occur on an average over the 4 h before the ﬁrst CNO or vehicle injections
for the trial to be included in the dataset. The order of CNO and matched vehicle
trials was randomized. Vehicle (1% DMSO/saline) or CNO (1mg kg 1 in DMSO/
saline) injected twice at 2-h intervals, and periods lasting 3.5 h after the ﬁrst
injection were analyzed.
EEG analysis. EEG was recorded and processed using the Neuroarchiver tool
(Open Source Instruments) and IgorPro (Wavemetrics Inc). The trace was centred
around 0V by subtraction of the average. Short (o100ms), high-amplitude
artifacts (‘glitches’) detected by threshold and periods with failed transmission were
removed. The Igor script ‘UnipolarPeakAreas.ipf’ was used to detect individual
negative deﬂections (spike-waves), and custom-written scripts in Igor extracted
their frequency as well as the coastline and power of the trace. The coastline was
determined as the sum of the absolute difference between successive points. EEG
epochs were also exported into Labview (National Instruments) to compute
Morlet-wavelet power spectra.
Behavioural seizure analysis. To establish a correlation between different types of
EEG-patterns and behaviour, we compared online scoring of seizures with EEG
traces analyzed ofﬂine. Behaviour was also video-recorded for reference. EEG traces
of 40min length, starting 2–3min after convulsant infusion, were divided into
4-s-intervals, and each interval was assigned a type of electrophysiological as well as
behavioural activity. Electrophysiological activity was scored as simple or complex
spike-waves, or as IF activity as described above (intervals without any spike-waves
were not counted and never coincided with behavioural convulsions). Motor
seizures were graded on a severity scale as follows: 0 (no obvious motor seizure), 1
(individual twitches of the contralateral limb or the head), 2 (repetitive shaking of
forelimb, head or body), 3 (whole body shaking, arching and rearing sometimes
accompanied by retrograde locomotion).
Automated epileptiform event counting. For tetanus toxin-induced epileptic
events, event sorting was based on six metrics extracted from each 1 s EEG epoch
and compared with a library of EEG events, which had previously been classiﬁed as
corresponding to seizures or artefacts7. The event-classifying routine stepped
through consecutive epochs, and measured baseline power as the lowest power
between 4 and 160Hz in any 1 s epoch during the preceding 20min. Epochs whose
power exceeded 5 baseline were deﬁned as putative events. For each such event,
the following six parameters were determined: Power (in the 4–160Hz band),
transient power (power in the 1–4Hz band), high-frequency power (60–160Hz),
spikiness (voltage range/standard deviation), voltage asymmetry (balance of points
exceeding two standard deviations on either side of the mean), and intermittency
(low-frequency power of the rectiﬁed high-frequency signal). A sigmoidal function
was applied to these six characteristics so as to obtain metrics bounded between
zero and one. The event library was constructed by an operator who, with reference
to synchronized video recordings, classiﬁed events as ‘no event’ (no obvious
electrographic or behavioural event), ‘short-high-frequency bursts’ (o250ms),
‘long-high-frequency bursts’ (4250ms, event power 46 baseline), ‘long-high-
frequency bursts of low amplitude’ (4250ms, event power 5–6 baseline),
‘high-frequency spikes’, ‘eating-related’ or ‘grooming-related’. As the algorithm
stepped through the subsequently identiﬁed events these were provisionally
identiﬁed as belonging to one or the other category according to its Euclidean
distance to previously classiﬁed neighbours. During the establishment of the
library, the identity of each new event proposed by the algorithm was overruled by
the observer if necessary until it reached a false allocation rate o1%. Once this
criterion was satisﬁed, all EEG data were classiﬁed without further operator
interference. A more complete description of the seizure detection algorithm with
source code is available at: http://www.opensourceinstruments.com/Electronics/
A3018/Seizure_Detection.html#Similarity%20of%20Events.
IF oscillations evoked by picrotoxin or pilocarpine were detected by using the
fast-Fourier transform of 3-s EEG segments in the range 5–14Hz (see also Fig. 2d).
The 3-second window was moved along the trace in 1-s steps. IF events were
deﬁned as periods where the peak magnitude between 5–14Hz exceeded a
threshold of 20–45mV, depending on the overall intensity of activity. Thresholds
were kept constant within each matched pair of CNO/vehicle trials.
Statistical analysis. Paired t-tests or Wilcoxon tests, or unpaired t-tests were
performed as appropriate using SPSS 20 (IBM). For seizure models, experimental
time was divided into 10-min periods including the 10min before injection as well
as seven consecutive 10-min periods after injection, and treatment effects were
assessed with repeated measures ANOVA.
Fluorescence and immunohistochemical analysis. Brains were removed and left
in 4% paraformaldehyde/phosphate-buffered saline (PBS) for 3–7 days at 4 C and
then washed in PBS. Coronal slices (50 and 100mm thickness) were cut on a
vibrating slicer and examined for native mCitrine-expression right after slicing for
each rat contributing to the dataset. Some of the 50 mm slices were processed
further: they were permeabilized in PBS, 0.15% Triton X-100 for 20min, blocked
with 10% horse serum (Vector Labs) for 1 h on a shaker and incubated for 2 days in
primary antibodies against CaMKIIa (rabbit, 1:500, Epitomics/Abcam) and
haemagglutinin (mouse, 1:1,000, Covance). Following three further washes in PBS
(10min), the sections were incubated in secondary antibodies (1:500, Invitrogen,
labelled with Alexa-488 and Alexa-546) overnight at 4 C, washed in PBS again
(four times, 10min) and mounted in Vectashield (Vector Labs). Images were
obtained with a confocal microscope at 25 magniﬁcation of the objective and
3 digital magniﬁcation.
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